OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 PRESS RELEASE OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Oxford, United Kingdom – 1 October 2024 –...

OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 PRESS RELEASE OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 Oxford, United Kingdom – 5th August 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology...

OMass Therapeutics Expands Leadership Team with Two New Appointments PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...